# A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients

> **NCT01742676** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Korea, Inc.** · enrollment: 100 (actual)

## Conditions studied

- Renal Transplantation
- Kidney Transplantation
- Stable Renal Recipients

## Interventions

- **DRUG:** ADVAGRAF
- **DRUG:** PROGRAF

## Key facts

- **NCT ID:** NCT01742676
- **Lead sponsor:** Astellas Pharma Korea, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2014-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01742676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01742676, "A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01742676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*